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Rheumatoid arthritis patient 
antibodies highly recognize IL-2 
in the immune response pathway 
involving IRF5 and EBV antigens
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Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by a progressive joint damage 
due to largely unknown environmental factors acting in concert with risk alleles conferring genetic 
susceptibility. A major role has been attributed to viral infections that include past contacts with 
Epstein-Barr virus (EBV) and, more recently, to non-protein coding sequences of human endogenous 
retrovirus K (HERV-K) integrated in the human genome. Molecular mimicry between viral and self 
proteins is supposed to cause the loss of immune tolerance in predisposed hosts. There are evidences 
that anti-IL-2 antibodies (Abs) are present in subjects affected by autoimmune diseases and may be 
responsible for alterations in regulatory T cell responses. In this study, we evaluated the levels of Abs 
against IL-2, viral epitopes and interferon regulatory factor 5 (IRF5) in 140 RA patients and 137 healthy 
controls (HCs). Ab reactivity reached the highest levels for IRF5, EBV and IL-2 (56%, 44% and 39%, 
respectively) in RA with significantly lower values among HCs (7–9%, p < 0.0001), which suggests a 
possible cross-reaction between IRF5/EBV homologous antigens and shifts in T cell balance disrupted by 
anti-IL-2 Abs.
Rheumatoid arthritis (RA) is a chronic autoimmune disease of complex pathogenesis that leads to a progres-
sive disability and major systemic complications with resulting socioeconomic concerns and premature death. 
Common manifestations involve synovial tissue inflammation and hyperplasia, autoantibody production, carti-
lage and bone destruction along with systemic features including pulmonary and cardiovascular complications1. 
RA is caused by largely unknown environmental factors acting in concert with risk alleles conferring genetic 
susceptibility2; among the former ones, a major role is attributed to viral infections putatively associated with 
numerous autoimmune diseases. The contribution of past contacts with Epstein-Barr virus (EBV) to RA patho-
genesis has been postulated for over 30 years3. Although EBV resides stably at low levels during the lifetime in 
about 95% of the adult population worldwide4, molecular mimicry between viral and self proteins is supposed 
to cause the loss of immune tolerance in predisposed hosts5–9. More recently, human endogenous retrovirus K 
(HERV-K) has been called into question10–14. Remnants of previous HERV-K infections are present in the human 
genome as non-protein coding sequences integrated into germline cells15. Transcription of these elements may 
be activated or stimulated by exogenous viruses such as EBV resulting in the production of antigenic peptides16.
We have previously reported increased humoral responses to EBV and HERV-K peptides in Sardinian RA 
patients17,18 that mirrored elevated antibody (Abs) titers directed against an epitope derived from Mycobacterium 
avium subsp. paratuberculosis (MAP) homologous to EBV inner tegument protein BOLF1 and human interferon 
regulatory factor 5 (IRF5)19. IRF5 is known to mediate virus-induced immune responses including expression of 
proinflammatory cytokines and its pro-apoptotic effect is activated by EBV in transformed cells20,21. In systemic 
lupus erythematosus (SLE), IRF5 was found to negatively regulate the expression of interleukin-2 (IL-2)22. IL-2 
is crucial for function, expansion and survival of regulatory T cells (Treg) and balance within this pathway is dis-
rupted in Th1-mediated autoimmune diseases such as RA, SLE or type 1 diabetes (T1D)23–25. Recently, the loss of 
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self-tolerance to IL-2 has been described in T1D subjects whose peripheral blood mononuclear cells yielded high 
quantities of INF-γ upon stimulation with IL-2-derived peptides26. Similarly, RA patients displayed raised levels 
of anti-IL-2 Abs supposed to affect IL-2 bioavailability necessary for Treg homeostasis.
In the present study, we evaluated humoral responses to synthetic IL-2 peptides in a larger cohort of Sardinian 
RA patients. A correlation analysis with seroreactivity to HERV-K and homologous EBV, MAP and IRF5 epitopes 
permitted to assess a possible cross-reactivity of the antigens supposedly involved in RA pathogenesis. Human 
autoantigens along with EBV elicited the highest responses, while the strongest correlation was found between 
IL-2 and HERV-K pointing at a potential pathway that links EBV-induced transactivation of retroviral proteins 
and the subsequent cytokine secretion mediated by IRF5.
Results
The potential to raise Ab responses differed between the two analyzed Il-2 peptides. IL-26–20KK elicited a higher 
Ab seroreactivity accounting for 39% (n = 55) among RA patients and 7% (n = 10) in HCs (p < 0.0001, Fig. 1A), 
while Abs against IL-256–70 were detected in 23% (n = 32) of RA subjects and 8% (n = 13) of HCs (p = 0.0031, 
Fig. 1B). However, the highest levels of autoreactive Abs were directed against IRF5424–434 observed in 56% 
(n = 79) of RA patients and only 9% (n = 13) of HCs (p < 0.0001, Fig. 1C). Slightly lower prevalence was observed 
for anti-BOLF1305–320 Abs found in 44% (n = 61) of RA subjects and 9% of HCs (p < 0.0001, Fig. 1D). Responses 
against Herv-Kenv19–37 and MAP_402718–32 were maintained at the same levels (9%) among HCs, while seroreac-
tivity of RA patients equaled 24% (n = 34, p = 0.0012, Fig. 1E) and 21% (n = 30, p = 0.0076, Fig. 1F), respectively. 
Despite antigen-related differences in single-type Abs prevalence, all results attained statistical significance with 
the highest AUC values for IL-26–20KK and IRF5424–434.
The prevalence of Abs against both IL-2 epitopes was additionally assessed in 34 samples of patients affected 
by neuromyelitis optica spectrum disorder (NMOSD). Only one patients displayed values above the established 
cut-off for IL-256–70 (2.9%, Fig. 1A) whereas lower means obtained for IL-26–20KK were mirrored by the absence of 
positive cases (Fig. 1B). Moreover, the responses of NMOSD patients were markedly lower compared not only 
to RA subjects, but also to HCs. The immunone response against the other peptides of this study in NMOSD 
patients has been evaluated in another study (manuscript submitted).
To test the specificity of humoral responses mounted against the selected peptides, 22 HCs and 22 RA patients 
were randomly selected from the study population and tested for seroreactivity against J0I929_HELPX1–11 control 
peptide derived from Helicobacter pylori homologous to human ZnT827. In both groups, half number of samples 
tested positive to at least one (HCs) or all (RA) of the previously assessed peptides. The observed mean values 
were slighty higher for HCs and corresponded to the absence of positive subjects compared to 9% (n = 2) among 
Figure 1. ELISA-based analysis of Abs reactivity against human, viral and MAP-derived peptides in RA, 
NMOSD and HCs. The sera were tested against plate-coated IL-26–20KK (B), IL-256–70 (A), IRF5424–434  
(C), BOLF1305–320 (D), Herv-Kenv19–37 (E) and MAP_402718–32 (F) peptides. Bars represent the 
median ± interquartile range. Thresholds for Abs positivity are indicated by dashed lines. Percentages of Abs 
prevalence respective to each group, AUC and P-values are indicated above the distributions.
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RA patients, however statistical significance was not attained (p = 0.07). Interestingly, RA individuals with multi-
ple Abs positivity presented lower mean values compared to HCs with single-peptide positivity (Fig. 2).
To define associations between the antigenicity of the assessed peptides we performed correlation analyses 
of Abs positivity values among RA patients (Fig. 3). The highest coefficients were obtained for the homologous 
epitopes BOLF1305–320, MAP_402718–32 and IRF5424–434 in pairwise plots (Fig. 3A) pointing at cross-reactivity due 
to shared amino acid sequence. Correlation trends of both IL-2 peptides were similar with respect to the other 
antigens (Fig. 3B,C): Herv-Kenv19–37 and MAP_402718–32 correlated moderately with either IL-26–20KK or IL-256–70, 
however IL-256–70/Herv-Kenv19–37 distribution corresponded to a slightly higher R2 value (Fig. 3B). Unexpectedly, 
weak to modest correlations were found between IL-2, IRF5424–434 and BOLF1305–320 (Fig. 3C).
We further evaluated multiple positivity to the assessed peptides in order to verify whether correlations 
between Ab titers find correspondence with the overlap in seroreactivity against IL-2 (Table 1). In contrast to mild 
correlations of both IL-2 epitopes plotted against IRF5424–434 or BOLF1305–320, double or triple humoral responses 
to these antigens were detected in a major number of subjects with distinctly higher percentages for IL-2/IRF5 
reflecting single-peptide Abs prevalence. On the other hand, responsiveness to Herv-Kenv19–37 overlapped well 
with the presence of anti-IL-256–70 Abs as expected from the correlation analysis and stood out also in triple pos-
itivity with positivity to IRF5424–434. Even though multiple responses among HCs are low in general, they visibly 
tend to diminish for Abs against at least three antigens.
Upon sex-related screening of RA samples, females showed higher mean Abs values and positivity prevalence 
for all peptides compared to males, however statistical significance was reached only for IRF5424–434 (p = 0.034). 
After classification of RA patients and HCs in three age groups (≤49, 50–59 and ≥60), the highest responsiveness 
was observed for BOLF1, IRF5 and IL-26–20KK (Table 2). This trend was clearly visible in the youngest RA group 
regardless of sex, however females maintained it more stably until the age of 59. In contrast to men, humoral 
responses of RA and HC women were not significant in the oldest group but this could be affected by a small 
number of elderly HCs in our study population. A general decrease in Ab positivity proportional to age was com-
mon to either male or female patients. Importantly, seroreactivity to IRF5 exceeded 93% in the youngest females 
and reached a 100% in ≤49 year-old males (one patient).
PCA analysis permitted to identify relationships between clinical variables and the selected epitopes with 
79.17% of cumulative variation describing four principal components (Table 3). Correlation between Ab 
values and two inflammatory parameters was low but attained a statistical significance that differed based 
on the analyzed measure: ESR correlated to Ab values towards IL-2 and HERV-K, while CRP yielded higher 
coefficients in plots with the homologous MAP, EBV and IRF5 antigens. No correlation with other clinical 
data was found.
Discussion
Recent reports on the loss of self-tolerance to IL-2 in autoimmune diseases encouraged us to evaluate the pres-
ence of anti-IL-2 Abs in Sardinian RA patients in association to antigens most frequently described as possible 
contributors to RA progression. Our results confirm the involvement of IL-2 in RA at higher rates compared to 
a French cohort (39% vs.15%, respectively)26 and is mirrored by a concomitant positivity to peptide antigens 
derived from EBV, HERV-K, MAP or human IRF5. The latter has been linked to acute inflammation as a fac-
tor promoting polarization of macrophages towards an inflammatory phenotype in antigen-induced RA mouse 
models and driving Th1/Th17 responses28–30.
In the present study, IRF5, together with the EBV surface tegument protein BOLF1 and IL-2, triggered the 
greatest response even though devoid of a good correlation with IL-2. This suggests that the association between 
the two human autoantigens may not be proportionally dependent on Ab titers but favour autoimmunity when a 
tolerance threshold is surmounted. In contrast, IRF5 correlated well with homologous BOLF1 and MAP epitopes 
pointing at molecular mimicry that leads to a probable cross-reactivity with the assessed environmental agents 
to which humans are constantly exposed. This was recently confirmed by the competitive inhibition assay in 
our previous study31. For IL-2, the best correlation was obtained in the plot with HERV-K. While reactivation 
Figure 2. Abs reactivity against the antigenic peptide derived from H. pylori in RA patients and HCs. Bars 
represent mean value ± interquartile range, while dashed lines indicate the positivity threshold. Despite 
sequence homology to human ZnT8 protein fragment, no significant differences in Abs levels were detected.
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of endogenous retroviral protein expression may elicit serological and cell-mediated responses, an uncontrolled 
expansion of Treg cells in subjects who lost self-tolerance to IL-2 or IRF5 may explain the development of auto-
immunity. Interestingly, over 30% of our RA cohort displayed anti-IL-2/IRF5 Abs in a highly significant double 
positivity (p < 0.0001) and a more frequent multiple seroreactivity was observed in RA patients compared to 
healthy controls (Table 1).
Figure 3. Scatter plots showing correlations between Abs titers in RA patients. Pairwise distributions are 
classified for homologous peptides (A), IL-26–20KK (B) and IL-256–70 (C). Each dot correspond to OD values 
obtained for a single patient.
IL-256–70 IL-26–20 KK
HCs RA HCs RA IL-2 BOLF1305–320 IRF5424–434 MAP_402718–32 Herv-K19–37
b 5 (3.65) 24 (17.14) 5 (3.65) 36 (25.17)
2 (1.46) 27 (19.28) 4 (2.92) 43 (30.71)
b 3 (2.19) 20 (14.28) 4 (2.92) 28 (20.00)
a 5 (3.65) 25 (17.86) 0 29 (20.71)
2 (1.46) 20 (14.28) 0 24 (17.14)
1 (0.73) 20 (14.28) 2 (1.46) 27 (19.28)
1(0.73) 24 (17.14) 3 (2.19) 33 (23.57)
0 19 (13.57) 2 (1.46) 27 (19.28)
1 (0.73) 17 (12.14) 0 19 (13.57)
1 (0.73) 23 (16.43) 0 27 (19.28)
0 19 (13.57) 1 (0.73) 26 (18.57)
0 19 (13.57) 0 23 (16.43)
1 (0.73) 17 (12.14) 0 20 (14.28)
0 19 (13.57) 0 19 (13.57)
0 16 (11.43) 0 19 (13.57)
Table 1. Multiple Abs prevalence in RA patients and HCs. Seroreactivity against IL-2 antigens was compared 
with humoral responses to MAP, EBV, HERV-K and human IRF5 peptides. The numbers of subjects positive 
for anti-IL-26–20KK and/or anti-IL-256–70 Abs are reported with relative percentages in brackets. Horizontal bars 
indicate Abs against at least two antigens identified in the samples with IL-2 referred to as both IL-26–20KK and 
IL-256–70. p < 0.0001 for all values except aIL-256–70 (p < 0.0002) and bIL-256–70 (p < 0.0003).
www.nature.com/scientificreports/
5SCientifiC RePoRTS |  (2018) 8:1789  | DOI:10.1038/s41598-018-19957-z
Major prevalence of Abs directed against all single peptides and higher mean Abs values obtained for RA 
females in a sex-related analysis point at a more grave disease course proper to women and highlight the involve-
ment of IRF5. This was mirrored by a strikingly high prevalence of Abs against IRF5 in the ≤49 year-old group 
independently of patients’ sex. An elevated general seroreactivity observed in the youngest group that decreases 
with age points at strong immune responses accompanying early disease onset.
A significant correlation between levels of anti-IL-2 Abs and measures of systemic inflammation 
(Table 3) is supportive of the hypothesis that anti-IL-2-driven impairment of Treg activity may alter auto-
immune processes and inflammatory burden. Other than expected, we did not find significant correlations 
between disease severity, immunosuppressive treatment, RF and ACPA status with levels and positivity of 
anti-IL-2 Abs. It should be acknowledged that all patients were under different immunosuppressive drugs 
at the moment of sample collection. The heterogeneity of treatment across subjects may have biased inter-
pretation and significance of associations between humoral responses and inflammatory measures. Further 
analysis of IL-2 levels, quantification of INF-γ upon stimulation with the analyzed peptides and Treg activity 
are needed to complete our observations. More numerous groups of the youngest patients at RA onset and 
elderly HCs would additionally permit to associate the efficacy of therapy in modulating serological and cell 
responses.
Materials and Methods
Subjects. Blood samples of 140 RA patients (34 males, 106 females; median age 58.95) and 137 healthy 
controls (HCs; 47 males, 90 females; median age 46.30) were collected in Vacutainer tubes for the separa-
tion of serum and further screening for Abs against IL-2, IRF5, MAP_4027, BOLF1 and HERV-K by indirect 
Gender Age (y) N Subjects BOLF1 P IRF5 P MAP_4027 P IL-2 56–70 P
IL-2 
6–20KK P Herv-K19–37 P
Females
≤49














65 HCs 8 (12,30%) 6 (9,2%) 5 (7,6%)
9 
(13,8%) 6 (9,2%) 9 (13,8%)
50–59















19 HCs 2 (10,52%) 1 (5,2%) 3 (15,78%) 1 (5,2%) 1 (5,2%) 1 (5,2%)
≥60























































23 HCs 0 3 (13,04%) 1 (4,3%) 1 (4,3%) 0 1 (4,3%)
≥60














9 HCs 0 1 (11,1%) 0 0 0 1 (11,1%)
Table 2. Age- and sex-related Abs prevalence in RA patients and HCs. The numbers of individuals responsive 
to single antigens are provided with relative percentages. Statistically significant values are highlighted in bold.
PC1 PC2 PC3 PC4
BOLF1 0,629 0,017 0,063 0,003
IRF5 0,732 0,014 0,037 0,004
MAP_4027 0,820 0,000 0,000 0,005
IL-256–70 0,685 0,042 0,012 0,008
IL-26–20KK 0,726 0,047 0,028 0,001
Herv-K 0,596 0,099 0,037 0,000
ESR 0,044 0,281 0,475 0,007
CRP 0,023 0,660 0,002 0,120
Age 0,041 0,065 0,590 0,015
Sex 0,054 0,206 0,004 0,727
Table 3. Correlation coefficients between inflammation measures, demographic data and seroreactivity relative 
to the selected antigens. All correlations are expressed as squared cosines of the variables.
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enzyme-linked immunosorbent assay (ELISA). RA patients who met the criteria of the American College of 
Rheumatology32,33 were enrolled from the outpatient clinic of the Rheumatology Unit, Department of Clinical 
and Experimental Medicine, University Hospital of Sassari, Italy. Clinical data collected during control med-
ical visits included information relative to the duration of RA, therapy (steroids, Tocilizumab, Rituximab, 
Abatacept, DMARDs, Etanercept, Adalimumab, Golimumab, Infliximab and Certolizumab anti-TNF-α), lev-
els of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) levels, positivity to rheumatoid factor 
and anti-cyclic citrullinated peptide (anti-CCP), Disease Activity Score-28 (DAS-28) and grade of disabil-
ity defined through the health assessment questionnaire (HAQ). 34 NMOSD patients (5 males, 29 females; 
median age 51.32) were enrolled at the Neurology Clinic of the University Hospital of Sassari and at the 
Department of Neurosciences, Biomedicine and Motion, University of Verona, Italy. HCs were recruited at the 
Blood Transfusion Center of Sassari, Italy. Demographic, clinical and laboratory characteristics of the partici-
pants are summarized in Table 4. Ethical clearance for the study protocols was achieved from the local health 
authority (Azienda Ospedaliero-Universitaria, protocols 1134/L-16/04/2013 and 1192/L-04/02/2014) and all 
methods were performed in accordance with national and regional regulations. All participants were resident 
in Sardinia and signed written informed consent.
Antigens. The following peptides synthesized commercially at >90% purity (LifeTein, South 
Plainfield, USA) were included in the study: IL-26–20KK (KK-LLSCIALSLALVTNS-KK) and IL-256–70 
(LTEMLTFKFYMPKKA) based on Pérol et al. with modifications26, IRF5424–434 (VVPV–AARL-LLE), 
MAP_402718–32 (AVVPVLAYAAARL-LL), BOLF1305–320 (AAVPVLAFDAARLRLLE) and Herv-Kenv19–37 
(VWVPGPTDDRCPAKPEEEG). In addition, J0I929_HELPX1–11 (MIIGGGVSGCA) derived from H. pylori qui-
none oxidoreductase, homologous to human ZnT827 was used as a control peptide. Moreover, wells containing no 
peptides adsorbed were included as negative control.
Enzyme-linked immunosorbent assays (ELISA) and statistical analysis. Indirect ELISA to detect 
specific Abs against the selected antigens was performed as described previously34. The optical density (OD) was 
read at a wavelength of 405 nm using SpectraMax Plus 384 microplate reader (Molecular Devices, Sunnyvale, 
CA 94089, USA). For data normalization, a highly responsive serum with Ab reactivity fixed at 1.0 arbitrary unit 
(AU)/ml was included in all experiments. The results were expressed as a mean of three separate experiments and 
the statistical analyses were performed using Graphpad Prism 6.0 software (GraphPad Software Inc., La Jolla, 
CA 92037, USA). Upon determination of sample distribution through D’Agostino-Pearson normality test, values 
between RA patients and HCs were compared using a two-tailed Mann-Whitney U test with p < 0.05 considered 
statistically significant. The cut-off for positivity was established in the interval 0.49–0.60 (AU)/ml based on the 
receiver operating characteristic (ROC) curve (Fig. 1) with ≥90% specificity and 95% confidence interval. Fisher’s 
exact test was employed to compare the percentages of positive subjects in the two groups. Correlations between 
variables were analyzed through principal component analysis (PCA) using XLSTAT software ver. 17 (Addinsoft, 
New York).
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